Hantavirus Outbreak Boosts Moderna Stock by 36%

Moderna's stock surged 36.08% from $43.69 to $59.45 in early May, driven by a hantavirus outbreak on the MV Hondius, according to BeInCrypto. The rally was fueled by three catalysts: a 260% year-over-year revenue increase to $389 million in Q1 2026, a collaboration with the US Army Medical Research Institute of Infectious Diseases on a hantavirus vaccine, and the publication of Phase 3 mRNA-1010 flu data in the New England Journal of Medicine. Moderna's stock is now consolidating near $54.05, forming a cup-and-handle pattern, with a potential breakout above $60.96.